United Kingdom and Ireland Oesophagogastric Cancer Group Cancer Update 2023

M.E. Booth, H.A. Clements (Lead / Corresponding author), J. Helbrow, M.A. Baxter, C.W. Bleaney, M.A. Hawkins, S.R. Markar, C.J. Peters, E.C. Smyth, T.D.L. Crosby

    Research output: Contribution to journalEditorialpeer-review

    Abstract

    Oesophagogastric (OG) cancer accounts for 4% of cancer incidence in the UK, with approximately 16,000 new cases per year, but is a less survivable cancer, causing 1 in 12 cancer deaths [1,2]. This poses a significant challenge to patients and healthcare providers. Recent research in OG cancer has focused on precision oncology, i.e. selecting the right treatment for the right patient. Studies have demonstrated improved outcomes with immune checkpoint inhibitors, targeted agents, advanced radiotherapy techniques, and multimodal treatments in selected patient cohorts in both adenocarcinoma and squamous cell carcinoma (SCC) histological subtypes [3]. Here, we present an overview of key advancements in the treatment of OG cancers from 2023. We discuss how the results of recent studies may impact practice and look ahead at the evolving OG cancer horizon.
    Original languageEnglish
    Number of pages9
    JournalClinical Oncology
    DOIs
    Publication statusE-pub ahead of print - 24 May 2024

    Keywords

    • Biomarkers
    • gastric cancer
    • Immunotherapy
    • oesophageal cancer
    • radiation oncology
    • surgical oncology

    Fingerprint

    Dive into the research topics of 'United Kingdom and Ireland Oesophagogastric Cancer Group Cancer Update 2023'. Together they form a unique fingerprint.

    Cite this